Randomised Trial Of Azithromycin To Eradicate Ureaplasma In Preterm Infants

ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION(2020)

引用 46|浏览16
暂无评分
摘要
Objective To test whether azithromycin eradicates Ureaplasma from the respiratory tract in preterm infants.Design Prospective, phase IIb randomised, double-blind, placebo-controlled trial.Setting Seven level III-IV US, academic, neonatal intensive care units (NICUs).Patients Infants 24(0)-28(6) weeks' gestation (stratified 24(0)-26(6); 27(0)-28(6) weeks) randomly assigned within 4 days following birth from July 2013 to August 2016.Interventions Intravenous azithromycin 20 mg/kg or an equal volume of D5W (placebo) every 24 hours for 3 days.Main outcome measures The primary efficacy outcome was Ureaplasma-free survival. Secondary outcomes were all-cause mortality, Ureaplasma clearance, physiological bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age, comorbidities of prematurity and duration of respiratory support.Results One hundred and twenty-one randomised participants (azithromycin: n=60; placebo: n=61) were included in the intent-to-treat analysis (mean gestational age 26.2 +/- 1.4 weeks). Forty-four of 121 participants (36%) were Ureaplasma positive (azithromycin: n=19; placebo: n=25). Ureaplasma-free survival was 55/60 (92% (95% CI 82% to 97%)) for azithromycin compared with 37/61 (61% (95% CI 48% to 73%)) for placebo. Mortality was similar comparing the two treatment groups (5/60 (8%) vs 6/61 (10%)). Azithromycin effectively eradicated Ureaplasma in all azithromycin-assigned colonised infants, but 21/25 (84%) Ureaplasma-colonised participants receiving placebo were culture positive at one or more follow-up timepoints. Most of the neonatal mortality and morbidity was concentrated in 21 infants with lower respiratory tract Ureaplasma colonisation. In a subgroup analysis, physiological BPD-free survival was 5/10 (50%) (95% CI 19% to 81%) among azithromycin-assigned infants with lower respiratory tract Ureaplasma colonisation versus 2/11 (18%) (95% CI 2% to 52%) in placebo-treated infants.Conclusion A 3-day azithromycin regimen effectively eradicated respiratory tract Ureaplasma colonisation in this study.
更多
查看译文
关键词
bronchopulmonary dysplasia,neonatology,prematurity,ureaplasma parvum,ureaplasma urealyticum
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要